Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs, patient-derived xenograft models from human brain metastases and phase 0 and window-of-opportunity trials are of utmost importance. See related article by Kabraji et al., p. 174.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-22-2853 | DOI Listing |
Publication Analysis
Top Keywords
brain metastases
8
brain metastasis
4
metastasis her2-positive
4
her2-positive breast
4
breast cancer
4
cancer evolving
4
evolving landscape
4
landscape trastuzumab
4
trastuzumab deruxtecan
4
deruxtecan her2-directed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!